A phase II study of Bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A cytokine Working Group (CWG) study

Journal of Immunotherapy

Volumn 36, Issue 9, 2013, Pages 490-495

  Dandamudi, Uday B ^a   Ghebremichael, Musie ^b   Sosman, Jeffrey A ^e   Clark, Joseph I ^f   McDermott, David F ^c   Atkins, Michael B ^g   Dutcher, Janice P ^h   Urba, Walter J ^i,j   Regan, Meredith M ^d   Puzanov, Igor ^e   Crocenzi, Todd S ^i,j   Curti, Brendan D ⁱ   Vaishampayan, Ulka N ^k   Crosby, Nancy A ^a   Margolin, Kim A ^l   Ernstoff, Marc S ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

ⁱ EARLE A CHILES RESEARCH INSTITUTE   (United States)

^j Providence Cancer Center   (United States)

^k WAYNE STATE UNIVERSITY   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

antiangiogenesis; immunotherapy; interleukin 2; renal cell cancer

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; VASCULOTROPIN;

ACUTE VASCULAR SYNDROME; ADULT; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLLAPSE; DEATH; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INTESTINE PERFORATION; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; VASCULAR DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84887077587     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000003     Document Type: Article

References (38)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
2. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens. 2002;11:37-42. (Pubitemid 34053336)
3. McDermott DF, Ghebremichael MS, Signoretti S, et al. The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2010;28(suppl):4514.
4. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132. (Pubitemid 46606294)
5. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-1278. (Pubitemid 28216581)
6. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141. (Pubitemid 41702632)
7. Mickisch GH, Garin A, van Poppel H, et al. European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferonalfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970. (Pubitemid 32913522)
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
9. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011;117:2637-2642.
10. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24. (Pubitemid 46630489)
11. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10(pt 2):6388S-6392SS.
12. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918. (Pubitemid 41103603)
13. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28:475-480.
14. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
15. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
16. Atkins MB. Interleukin-2: clinical applications. Semin Oncol. 2002;29(suppl 7):12-17. (Pubitemid 34620430)
17. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
18. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumorinduced immune suppression. Blood. 2003;101:4878-4886. (Pubitemid 36857749)
19. Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963-2970. (Pubitemid 29493976)
20. Basu A, Hoerning A, Datta D, et al. Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol. 2010;184:545-549.
21. Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171-6180.
22. Na X, Wu G, Ryan CK, et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003;170(pt 1): 588-592. (Pubitemid 36870265)
23. Nicol D, Hii SI, Walsh M, et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol. 1997;157:1482-1486. (Pubitemid 27130856)
24. Schwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic effects of intranodal autologous tumor lysatedendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009;15:4986-4992.
25. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349: 427-434. (Pubitemid 36910021)
26. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536-4541. (Pubitemid 350035309)
27. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111. (Pubitemid 350296300)
28. Cox DR, Snell EJ. Analysis of Binary Data. 2nd ed. London: Chapman; 1989.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
30. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGFtargeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009;32:181-185.
31. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422-5428.
32. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14: 6674-6682.
33. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008;111:5610-5620.
34. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799.
35. Jensen HK, Donskov F, Nordsmark M, et al. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res. 2009;15:1052-1058.
36. Wada J, Suzuki H, Fuchino R, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 2009;29:881-888.
37. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase Iproducing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553-1560.
38. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166. (Pubitemid 28544331)